Data from FDA (Food and Drug Administration, USA) - Curated by EPG Health - Last updated 19 April 2017


Corifact is a Factor XIII concentrate indicated for adult and pediatric patients with congenital Factor XIII deficiency for:
• Routine prophylactic treatment
• Peri-operative management of surgical bleeding (1).

Full Prescribing information

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Pain, Agitation and Delirium (PAD) Management

Pain, Agitation and Delirium (PAD) Management

Discover the latest guidance on assessment and management of pain, agitation and delirium for patients requiring sedation.

+ 4 more

Load more

Related Content

Advisory information


• Do not use in patients with known anaphylactic or severe systemic reactions to human plasma-derived products (4).

Special warnings and precautions

• Hypersensitivity reaction may occur (5.1).
• Inhibitory antibodies have been detected in patients receiving Corifact (5.2).
• Thrombotic events have been reported with Corifact (5.3).
• May carry a risk of transmitting infectious agents e.g., viruses, and theoretically, the Creutzfeldt-Jakob Disease (CJD) agent (5.4).

Adverse reactions

• The most common adverse reactions reported in clinical trials (>1%) were joint inflammation, hypersensitivity, rash, pruritus, erythema, hematoma, arthralgia, headache, elevated thrombin-antithrombin levels, and increased blood lactate dehydrogenase (6).
• Serious adverse reactions reported in clinical trials were hypersensitivity, acute ischemia, and neutralizing antibodies against FXIII (5.1, 6).

Usage information

Dosing and administration

For intravenous use only.
Dose (2.1)
• 40 International Units (IU) per kg body weight; rate not to exceed 4 mL per min.
• Adjust dose ±5 IU per kg to maintain 5% to 20% trough level of FXIII activity.

Dose Adjustment Using the Berichrom Activity Assay (2.1)

FXIII Activity Trough Level (%) Dosage Change
One trough level of <5% Increase by 5 IU per kg
Trough level of 5% to 20% No change
Two trough levels of >20% Decrease by 5 IU per kg
One trough level of >25% Decrease by 5 IU per kg

Administration (2.2)
• Administer at a rate not exceeding 4 mL per minute
• For routine prophylaxis, administer every 28 days
• For peri-operative management of surgical bleeding, individualize dose based on the patient’s FXIII activity level, type of surgery, and clinical response
• Following are dose adjustment examples for peri-operative management in reference to the patient’s last prophylactic dose:

Dose Adjustment for Peri-operative Management

Time Since Last Dose Dose
Within 7 days Additional dose may not be needed
8 – 21 days Additional partial or full dose may be needed based on FXIII activity level
21 – 28 days Full prophylactic dose
Use in special populations
• Pregnancy: No human or animal data. Use only if clearly needed (8.1).
• Pediatric: Shorter half-life and faster clearance compared to adults. Dose adjustment may be needed (8.4).

More information

Category Value
Authorisation number BLA125385
Orphan designation No
Product NDC 63833-518
Date First Approved 17-02-2011
Marketing authorisation holder CSL Behring, GmbH